These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 38508137)

  • 1. DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
    Kirk AM; Crawford JC; Chou CH; Guy C; Pandey K; Kozlik T; Shah RK; Chung S; Nguyen P; Zhang X; Wang J; Bell M; Mettelman RC; Allen EK; Pogorelyy MV; Kim H; Minervina AA; Awad W; Bajracharya R; White T; Long D; Gordon B; Morrison M; Glazer ES; Murphy AJ; Jiang Y; Fitzpatrick EA; Yarchoan M; Sethupathy P; Croft NP; Purcell AW; Federico SM; Stewart E; Gottschalk S; Zamora AE; DeRenzo C; Strome SE; Thomas PG
    Cell Rep Med; 2024 Mar; 5(3):101469. PubMed ID: 38508137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
    Bauer J; Köhler N; Maringer Y; Bucher P; Bilich T; Zwick M; Dicks S; Nelde A; Dubbelaar M; Scheid J; Wacker M; Heitmann JS; Schroeder S; Rieth J; Denk M; Richter M; Klein R; Bonzheim I; Luibrand J; Holzer U; Ebinger M; Brecht IB; Bitzer M; Boerries M; Feucht J; Salih HR; Rammensee HG; Hailfinger S; Walz JS
    Nat Commun; 2022 Oct; 13(1):6401. PubMed ID: 36302754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
    Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.
    Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
    Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1.
    Shirani M; Levin S; Shebl B; Requena D; Finkelstein TM; Johnson DS; Ng D; Lalazar G; Heissel S; Hojrup P; Molina H; de Jong YP; Rice CM; Singhi AD; Torbenson MS; Coffino P; Lyons B; Simon SM
    Cancer Res; 2024 Aug; 84(16):2626-2644. PubMed ID: 38888469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.
    Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
    Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
    Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
    Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
    Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
    Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
    Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
    Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Kastenhuber ER; Lalazar G; Houlihan SL; Tschaharganeh DF; Baslan T; Chen CC; Requena D; Tian S; Bosbach B; Wilkinson JE; Simon SM; Lowe SW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(50):13076-13084. PubMed ID: 29162699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient.
    Balbeur S; Dumortier A; Mergen J; Libbrecht L; Torbenson M; Boulanger C; de Ville de Goyet M; Van Damme A; Brichard B
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28060. PubMed ID: 31736218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma.
    Dinh TA; Jewell ML; Kanke M; Francisco A; Sritharan R; Turnham RE; Lee S; Kastenhuber ER; Wauthier E; Guy CD; Yeung RS; Lowe SW; Reid LM; Scott JD; Diehl AM; Sethupathy P
    Cell Mol Gastroenterol Hepatol; 2019; 7(4):803-817. PubMed ID: 30763770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
    Ma RK; Tsai PY; Farghli AR; Shumway A; Kanke M; Gordan JD; Gujral TS; Vakili K; Nukaya M; Noetzli L; Ronnekleiv-Kelly S; Broom W; Barrow J; Sethupathy P
    PLoS Genet; 2024 Mar; 20(3):e1011216. PubMed ID: 38512964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
    Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
    Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
    Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
    Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.
    Toyota A; Goto M; Miyamoto M; Nagashima Y; Iwasaki S; Komatsu T; Momose T; Yoshida K; Tsukada T; Matsufuji T; Ohno A; Suzuki M; Ubukata O; Kaneta Y
    Biochem Biophys Res Commun; 2022 Sep; 621():157-161. PubMed ID: 35839742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas.
    Reid LM; Sethupathy P
    Hepatology; 2016 Feb; 63(2):662-4. PubMed ID: 26505878
    [No Abstract]   [Full Text] [Related]  

  • 18. DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling.
    Kim SS; Kycia I; Karski M; Ma RK; Bordt EA; Kwan J; Karki A; Winter E; Aktas RG; Wu Y; Emili A; Bauer DE; Sethupathy P; Vakili K
    PLoS One; 2022; 17(2):e0263829. PubMed ID: 35167623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.
    Lalazar G; Simon SM
    Semin Liver Dis; 2018 Feb; 38(1):51-59. PubMed ID: 29471565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.
    Graham RP; Yeh MM; Lam-Himlin D; Roberts LR; Terracciano L; Cruise MW; Greipp PT; Zreik RT; Jain D; Zaid N; Salaria SN; Jin L; Wang X; Rustin JG; Kerr SE; Sukov WR; Solomon DA; Kakar S; Waterhouse E; Gill RM; Ferrell L; Alves VA; Nart D; Yilmaz F; Roessler S; Longerich T; Schirmacher P; Torbenson MS
    Mod Pathol; 2018 Jan; 31(1):141-149. PubMed ID: 28862261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.